Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-15

Study Completion Date

2020-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate of the potential benefit of acute pretreatment with high dose atorvastatin (80 mg) in reduction of the incidence of CIN in diabetic patients indicated for elective coronary intervention.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography

NCT02113540

Contrast Induced Nephropathy

UNKNOWN PHASE3

High Dose Atorvastatin for Preventing Contrast-induced Nephropathy

NCT02114346

Contrast-Induced Nephropathy

COMPLETED PHASE2/PHASE3

Statins for Prevention of Contrast Induced Nephropathy

NCT00770796

Contrast Induced Nephropathy

COMPLETED PHASE4

Atorvastatin Effects On Arterial Stiffness In Hemodialysis

NCT04472637

Arterial Stiffness

COMPLETED PHASE2

The Role of Statins in the Prevention of Contrast-induced Acute Kidney Injury in Patients With Cardiovascular Diseases

NCT04666389

Contrast-induced Acute Kidney Injury Cardiovascular Diseases

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a prospective, multi-center, randomized, placebo-controlled study. The ethical committee of the Faculty of Medicine, Assiut University approved the study protocol.

200 diabetic patients with indication for coronary intervention participated in the study. 100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention (statin group) and 100 patients received placebo (control group). An informed written consent for participating in the study was obtained from each participant.

Exclusion criteria:

1. Current statin treatment within the previous three months.
2. Chronic renal failure patients on renal dialysis, or serum creatinine more than 1.5 mg/dl.
3. Severe co-morbidities i.e. patients with cancer, advanced liver cirrhosis.
4. Contraindications to statin therapy.
5. Contrast media injection within the preceding 10 days.
6. Pregnancy.
7. Refusal of consent. (B) Methodology:

All study patients were subjected to:

1. Full clinical history: including age, sex, history of smoking, hypertension, history of previous percutaneous coronary intervention (PCI), duration of diabetes mellitus (DM) and type of anti-DM treatment.
2. Thorough physical examination focusing on:

* General examination including intra-procedural hemodynamic assessment.
* Cardiac examination to elicit manifestations of heart failure.
3. Echocardiography searching for wall motion abnormalities and estimation of left ventricular systolic function.
4. Initial venous blood samples for determination of hemoglobin level and serum creatinine before the procedure. Follow up for serum creatinine at 48 hours post-procedure was done.

CIN was stated as a raising of serum creatinine of more than 25% or ≥0.5 mg/dl (44 μmol/l) from initial level within 48 hours of the angiographic procedure and after excluding other factors that may cause nephropathy such as nephrotoxic drugs.
5. All patients received clopidogrel (600 mg) or ticagrelor (180 mg). Any nephrotoxic drugs (i.e., metformin, non-steroidal anti-inflammatory drugs) were withdrawn on admission.
6. Coronary intervention was done using the same non-ionic, low-osmolar contrast medium (Iopamidol; Scanlux, Sanochemia, Austria) in all cases.

After the procedure, TIMI flow of the culprit artery was assessed, as well as the volume of used contrast media and time of X-ray exposure.
7. Statistical analysis:

Data were processed by statistical package for the social sciences (SPSS, version 20. 0). Descriptive statistics for interval and ordinal variables were calculated such as the ranges, means, and standard deviations, whereas, for categorical variables, the frequencies and percentages were reported. Student t-test or paired t-test, as appropriate, were used to compare normal and continuous variables. Chi-square test was used for comparing categorical variables. The level of significance was stated at P \< 0.05. Receiver operating curves (ROC) were plotted and area under the curve (AUC) was assessed for some studied variables. Sensitivity and specificity were calculated at a cutoff point. A p value of \<0.05 was considered significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

200 diabetic patients with indication for coronary intervention participated in the study. 100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention (statin group) and 100 patients received placebo (control group).

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Statin group

100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention

Group Type ACTIVE_COMPARATOR

Atorvastatin

Intervention Type DRUG

Patients received 80 mg atorvastatin before elective coronary angiography

Placebo group

100 patients received placebo

Group Type PLACEBO_COMPARATOR

Atorvastatin

Intervention Type DRUG

Patients received 80 mg atorvastatin before elective coronary angiography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin

Patients received 80 mg atorvastatin before elective coronary angiography

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

statin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 200 diabetic patients with indication for coronary intervention participated in the study

Exclusion Criteria

1. Current statin treatment within the previous three months.
2. Chronic renal failure patients on renal dialysis, or serum creatinine more than 1.5 mg/dl.
3. Severe co-morbidities i.e. patients with cancer, advanced liver cirrhosis.
4. Contraindications to statin therapy.
5. Contrast media injection within the preceding 10 days.
6. Pregnancy.
7. Refusal of consent.

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No